Why DIGIPHARM ICO?

features

Making healthcare
AFFORDABLE
for everyone

features

Platforms will be
BUILT & READY
before end of ICO

features

Already working with
WORLD’s LARGEST
health institutions

features

ICO within
SWISS GOVERNMENT
Financial Market Authority Compliance

A credible ICO - protecting the value of your tokens

At DIGIPHARM we know people are rightly skeptical about many ICOs - but DIGIPHARM is different. We’ve chosen to become one of the first fully regulated ICOs which means we adhere to strict Swiss government regulations that protect the tokens you buy from us.

Institutions worldwide know about the potential of value-based healthcare and trust the DIGIPHARM project as well as the team behind it. We have the ingredients for a thriving business and ICO.

features

Unique Partnership

DIGIPHARM is pleased to announce our strategic & technical partnership with Swisscom Blockchain as our full-stack development partners, the blockchain subsidiary of the Swiss state-owned telecom provider, Swisscom.

What is DIGIPHARM?

We believe that no one should have to pay full-price for healthcare treatments that don’t work. That’s why we’re using our industry expertise to pioneer the transformation of healthcare to a value-based model. We use blockchain technology and smart contracts to provide the world's first, fully independent, value-based healthcare platforms -

helping patients worldwide to get the healthcare they deserve, at prices they can afford.

Problem

Patients are not getting the healthcare they deserve

features
Aging Populations
features
Rise in chronic disease
features
Rising cost of treatments
features
Inefficiency & wastage

Solution

features

Value-based healthcare with DIGIPHARM

Value-based healthcare addresses the uncertainty surrounding the cost of treatment relative to patient outcomes. It rewards manufacturers & providers for improving patient outcomes, incentivises innovation, & encourages the transition to patient centric healthcare.

DIGIPHARM bypasses infrastructural limitations to:

  • Implement value-based pricing agreements using blockchain technology.
  • Develop unprecedented evidence platforms.
  • Reward patients for contributing their data.

DIGIPHARM Blockchain Solutions

Ready before the end of the ICO for two good reasons. The first is driven by market need, we’re already working with the world’s largest health institutions and demand for the platforms requires urgency. Secondly, because the DIGIPHARM ICO is governed by SWISS regulations, we’re obliged to protect the value of your tokens by building working platforms by the time the tokens are released. Unlike other ICO’s, DIGIPHARM is more than just an idea. You can be confident in buying DPH tokens.

features

REIMBURSE

World’s first blockchain & smart contract platform for performance-based flexible pricing of pharmaceuticals, medical devices, wider healthcare provision and community care.

  • Fully automated
  • Patient tracking
  • Low cost
  • Scalable worldwide

DIGIHEALTH

Your fair pricing healthcare app on the blockchain.

  • Reduce costs of healthcare treatments
  • Receive rewards for sharing data
  • Access real-time health information on current conditions & treatments
features

PIPELINE PROJECTS

The following projects are currently under development, they will not be ready by the ICO but remain vital to how DIGIPHARM will revitalise the healthcare industry.

Token Sale Information

The DIGIPHARM Token is a strong utility token that is key to the functionality of our platforms. As adoption of our platforms increase, the demand for the token increases. This gives token holders an incentive.

Token name:

DPH

Payout:

Minted & distributed to your ETH wallet after ICO

Total Token Supply:

100,000,000

Tokens Available for Sale:

50,000,000

Price:

1 DPH = $ 0.45 USD

Accepted Cryptocurrencies:

ETH , BTC

Minimum Cap:

$ 5m USD

Maximum Cap:

$ 15m USD

Distribution & Usage

Initial Token Distribution

token-distribution

Sale Proceed Allocation

funding-use

Partners

Swisscom Blockchain
Engene

Who we work with

Froriep
Crypto Valley Member
ECH Alliance
Swiss Digital Health
Business & Technical

Roadmaps

Unlike most ICOs that are unregulated, DIGIPHARM are required by FINMA to have a working model of the platform ready by the time the tokens are released following the ICO. That makes this a uniquely reliable ICO to invest in.

Business

Technical

Meet the Team

The DIGIPHARM Team combines a passion for healthcare, industry expertise & a proven track record in all the areas needed to make this project successful.

Ahmed Abdulla
Founder/CEO

team

Ahmed Abdulla

Founder/CEO

Health economist, expert member at UN/CEFACT. Previously at Roche & health science organisations.

Health economics, market access & pricing professional with experience across the medicinal lifecycle.

Previously at Roche, LRiG, PRA health sciences, University of Swansea & International Health Care Ltd. Several publications in high impact journals. Ahmed is also a Blockchain expert in Healthcare (UN/CEFACT) at the United Nations Economic Commission for Europe.

Zach Daniels
CTO

team

Zach Daniels

CTO

Tech professional, early blockchain adopter & experienced crypto trader

Experienced Network & DevOps Engineer & Blockchain Architect, vast experience with cryptocurrency & ICOs having been a part of over 30 projects in the space.

Hassan Chaudhury
Chief Commercial Officer
team

Hassan Chaudhury

Chief Commercial Officer

Hassan is a founding director and Chief Commercial Officer at Health iQ - a leading real world evidence agency based in the UK. His background is in health and social care, specifically in NHS informatics, public health and commissioning. He is an expert in developing solutions around real world data having spent many years consulting internationally with major pharmaceutical and medical device companies. Hassan currently holds a post as an Honorary Research Officer at Imperial College London for his work in eHealth and Big Data and is also a Committee Member of the PM Society.

Dr. Mohamed Abdulla
Chief Medical Officer
team

Dr. Mohamed Abdulla

Chief Medical Officer

Medical doctor currently practising in the UK. Graduated from King’s College London, School of Medicine. During his years training to become a general practitioner, he maintained a key interest in international healthcare by assisting hospitals in the middle east with equipment procurement, process review & staff training schemes.

Ralf Gerteis
Commercial Strategy
team

Ralf Gerteis

Commercial Strategy

Growth & internationalization Expert, International SAP/Management Consultant, tech & blockchain enthusiast with profound expertise in business development & cooperations. More than 8 years of management experience within the pharmaceutical industry with Novartis.

Steve Sibert
Information Systems Manager
team

Steve Sibert

Information Systems Manager

IT and Networking specialist with nearly 10 years of experience working with local IT systems and carrier grade networks.

Meredith Darden
Digital Marketing Lead
team

Meredith Darden

Digital Marketing Lead

Digital marketing specialist, Communications specialist at PIVX & crypto community influencer with a passion for blockchain technology.

Johannes Kern
Strategic Marketing
team

Johannes Kern

Strategic Marketing

A strategic marketing expert with a strong background in entrepreneurship, organisational development & online community building. Johannes leverages data driven approaches to make marketing strategies effective. Before joining Swisscom Blockchain AG hehad built one of Europe's largest networks for nascent startups, cofoundme.org. Johannes has studied at the University of St. Gallen, as well as at Stellenbosch University in South Africa & the Universidad Adolfo Ibañez in Santiago de Chile.

Alexey Popov
Web Engineering
team

Alexey Popov

Web Development

Over 10 years of experience in web development & graphic design. I.a. front-end/ web development for EY & Swisscom Blockchain AG. Cooperation as an adviser & core team member for crypto startups.

Participation at Hack the Valley in Zug, Switzerland for Ernst & Young. One of the last projects is ICO website for Welt der Wunder.

Michael Gubert
UI/UX Design
team

Michael Gubert

UI/UX Design

Michael is a media designer, illustrator & product photographer with over 6 years of experience in designing & developing high quality content for clients across financial services, retail & sports. Worked for Ernst & Young, Swisscom, Welt der Wunder, he specializes in UI /UX design for web sites, vector graphic & illustrations.

Alexander Sverdlov
Cybersecurity Strategy
team

Alexander Sverdlov

Cybersecurity Strategy

Previously at Microsoft, Hewlett-Packard & Axway. Consulted numerous central banks, telecom & financial organizations worldwide on cyber security & breach prevention. Author of Building a cyber fortress.

Gerard Slevin
Country Development & Operations
team

Gerard Slevin

Country Development & Operations

Gerard is founder of Salutem Insights, a health economic, market access and educational company. He has consulted for many major pharmaceutical companies in HTA, pricing and reimbursement strategies.

He is a qualified Health Economist, holds an MSc in Health Economics and Pharmacoeconomics and a BA in Economics and Mathematics. Gerard has vast experience in a wide variety of roles in pharmaceuticals (Helsinn Group and Clonmel Healthcare), finance (Statestreet International Bank, Deutche Bank and Bank of Luxembourg), journalism and academia.

Daniel Ryan
B2B Solutions Manager
team

Daniel Ryan

B2B Solutions Manager

Daniel has extensive knowledge of the healthcare sector in Ireland, having worked both in hospital and primary care settings. After qualifying from UCD in Radiography, Daniel subsequently completed a Masters in Pharmacy from the University of Brighton and went on to establish a thriving community pharmacy business and osteoporosis clinic. He has a keen interest in marketing, acquired from experience garnered in the sales and marketing division of Guinness Ireland.

Bobby Kaura
Business Development
team

Bobby Kaura

Business Development

Pharmaceutical business development executive with vast experience & proven track record of delivering innovative projects to completion. Background includes NHS, Roche, Illumina, ThermaProx & PWC.

Debra De Silva-Sun
HEOR & Pricing Analyst
team

Debra De Silva-Sun

HEOR & Pricing Analyst

Health Economics & outcomes research professional with experience in evidence-based health service research & policy evaluation. Previously at Roche, Vista Health & the University of Lucerne. Experienced health care professional with over 12 years of providing services in the Australian, Singaporean & Swiss healthcare systems.

Peter Sandbach
Communications Director
team

Peter Sandbach

Communications Director

Corporate communications specialist with extensive background across the pharmaceutical industry. Formerly head of communications at Roche & Syngenta.

Dr. Hasham Al-Meshhedani
Patient Engagement
team

Dr. Hasham Al-Meshhedani

Patient Engagement

Anaesthetics & Critical Care Specialist. Experience in multiple medical specialties including Oncology, Cardiology, Respiratory Medicine, Emergency Medicine, General Surgery & Endocrinology. Involved in medical education & the use of technology to advance Point of Care Learning & healthcare efficiency.

Dr. Rami Radwan
Clinical Relations
team

Dr. Rami Radwan

Clinical Relations

Postdoctoral surgical registrar in the UK. Collaborator on regional, national & international evidence based surgery with numerous publications in high impact medical journals. Active involvement in the development of digital health technology.

Jenny Hao Koppelkamm
Market Access and Pricing expert, previously at Pfizer, Novartis, and Takeda
team

Jenny Hao Koppelkamm

Market Access and Pricing expert, previously at Pfizer, Novartis, and Takeda

Expert in global market access, pricing and reimbursements, and government affairs with 20+ years experiences in pharmaceutical and medical device industries.

Previously at Pfizer, Novartis and Takeda. Graduated from Capital Medical University in China and MBA from the US. Have led global market access projects from product launch all through the lifecycle, collaborated with multiple organizations including government agencies and academia, developed innovative solutions to optimize market and patient access.

Adel Al-mofadaly
Regional director MENA
team

Adel Al-mofadaly

Regional director MENA

Pricing, market access, & HE professional with experience in Drug Use Utilization, VBP & Health policy. Previously at Saudi Food and Drug Authority & Security Forces Hospital. Over 12 years of experience providing services in clinical and managerial sitting.

Advisors

Rolf Günter
Legal Counsel
team

Rolf Günter

Legal Counsel

Rolf Guenter has a long lasting, proven track record as an advisory lawyer, general manager & board member of SME’s. Additionally he served as director in the insurance industry. Besides his activities in operational management, he has extensive experience from diverse, successfully managed projects.

Sven Möller
ICO Advisor
Swisscom Blockchain
team

Sven Möller

ICO Advisor
Swisscom Blockchain

A former manager at one of the Big 4, Sven is a recognized blockchain expert that has gained extensive experience as IT architect & project leader in numerous industries. During his career he has been involved in the development of several applications, this includes the management of technical solutions, smart contracts, marketing & overlooking general strategy.

Lucas Cervigni
Strategic Business Development
team

Lucas Cervigni

Strategic Business Development

Lucas is an Author, TV Host, International Business Development Advisor in FinTech and Blockchain Partner @ Vesicas Fintech Consulting, Co-Founder in + 15 Companies, Author @ BlockChain in Practice / The BitCoin Paradigm / BrickCoin - A solution for today’s global financial fragility. He is Advisor, Investor and International Panelist to the Crypto World who was named as one of the 50 most influential people in Blockchain in 2016.

Sam Mantle
Health & Life Sciences Technology Advisor
Luxoft
team

Sam Mantle

Health Technology Advisor
Luxoft

A dynamic global business leader & technology executive. Sam is currently the Managing Director of Healthcare & Life Sciences at Luxoft, he was formerly the Global Head of R&D IT at Novartis. He has a strong track record of business partnership, digital transformation, successful IT delivery & talent development across diverse geographies & functional areas.

Sam is passionate about leveraging technology to realise business value & high performance in Healthcare, Life Sciences & data driven companies. He is equipped with an agile, collaborative & entrepreneurial mind-set combined with a willingness to challenge his team, peers & business executives to achieve ambitious goals.

Anas Aman
Quality & Testing
IBM
team

Anas Aman

Quality & Testing
IBM

Experienced Test Manager focused on improving quality delivery & improving processes. Has a strong QA delivery track record in the Health Care, Financial, Transportation, & Public Sector industries. Currently leading the Mobile & SAP QA teams at IBMs NS CIC.

Waldemar Scherer
Life Sciences Blockchain Advisor
Swisscom Blockchain
team

Waldemar Scherer

Life Sciences Blockchain Advisor
Swisscom Blockchain

Waldemar Scherer is Head of Enterprise Blockchain at Swisscom Blockchain. With his team he advises private, institutional & governmental clients in adopting blockchain technology to their business operations. As a former manager at EY & consultant at HP, Waldemar is an experienced IT advisory professional. In his free time, he is an avid sportsman, participating in obstacle runs, scuba dives & climbing tours.

Lloyd Jefferies
CRM Advisor
KPMG
team

Lloyd Jefferies

CRM Advisor
KPMG

Senior CRM consultant & technical solutions architect currently based in the UK with KPMG, formerly lead application developer.

Per-Olof Thuresson
Health Economist
Roche
team

Per-Olof Thuresson

Health Economist
Roche

Global health economics manager at Roche, the worlds largest biotech company, with a keen interest in the influence of technology on the pharmaceutical reimbursement process. Developed intra-organisational health economic modelling apps & authored numerous publications in high impact journals.

Fadi Chehadah
Health Economist
NICE UK
team

Fadi Chehadah

Health Economist
NICE UK

Health economist at NICE UK, with previous experience in HTA & MTA appraisals at leading academic institutions such as the Centre for Health Economics at the University of York & the Academic Unit of Health Economics at the University of Leeds.

Kamal Youssefi
Enterprise Blockchain Advisor
Swisscom Blockchain
team

Kamal Youssefi

Enterprise Blockchain Advisor
Swisscom Blockchain

Kamal has extensive experience in managing & delivering industrial level solutions using SAP & blockchain technology. Formerly a senior SAP advisor & blockchain engineer at one of the Big 4. He is an expert in systems integration with a thorough understanding of regulatory compliance, financial cryptography & data security.

James Gannon
E-Compliance Advisor
Novartis
team

James Gannon

E-Compliance Advisor
Novartis

James Gannon is the Global Head of Technical Compliance for Emerging Technologies at Novartis AG. Based in Basel Switzerland, James has over 10 years of experience in advising large corporations & high technology startups on cyber security policy & quality regulatory affairs as they relate to adoption of new & emerging technologies in the healthcare market.

Alice Hlidkova
Visionary, Futurist, and a blockchain consultant
team

Alice Hlidkova

Visionary, Futurist, and a blockchain consultant

Alice Hlidkova is a visionary, futurist, and a blockchain consultant and writer, based in Chicago, USA. She has vast experience in helping startups scale international markets successfully. Alice founded her creative consulting agency, Through the Changing Glass LLC to advise tech startups on positioning and capital raise in Silicon Valley. She is also the co founder of New Economies LTD the media company and the parent of neweconomies.com, a leading blockchain news portal.

FAQ

What is DIGIPHARM?

DIGIPHARM combines industry expertise & revolutionary blockchain technology to pioneer the transformation of healthcare to a value-based approach.

How do I benefit from the ICO Token?

Businesses built using the blockchain are the future. And value-based healthcare is the future of the healthcare industry. DIGIPHARM combines both to solve the problems of a multi-trillion dollar industry. This is your chance to be among the first in the world to support the idea & benefit from the platform - as well as the potential increase in token demand as more people buy tokens & use the platform globally.

When can I trade using DPH?

DPH will be available on exchange once ICO concludes. We can’t give an exact date at this time, but we are actively seeking exchange partnerships.

How can I participate in the ICO Token sale?

Just click any ‘Buy Tokens Now’ button & follow the instructions.

What currencies are accepted to purchase DPH?

Bitcoin, Ethereum

What is the total supply?

There are 50,000,000 (fifty million) DPH tokens available in total for public sale. 15,000,000 available in the presale. 35,000,000 in the main sale. The total supply of DPH is 100,000,000.

What happens if caps are not met?

In the event the softcap isn’t met, all funds will be returned to investors.

Is there a minimum & maximum investment amount?

There are no minimum or maximum investment amounts

How much will each token cost during presale & main sale?

There is a 30% presale bonus. During the main sale, the cost per token depends at which stage you buy. There are stage 1 & 2 Bonus of 20% & 10% respectively. Towards the end of the sale the token will only be available at the full price of $0.45 per token.

Are DPH tokens resellable?

Yes. DPH is an ERC20 token, & will be available on exchange once ICO concludes. We can’t give an exact date at this time, but we are actively seeking exchange partnerships.

When will the token sale launch?

To be announced

How will tokens be used?
DIGIHEALTH:

DPH tokens will be used for access rights to the Digihealth platform. Research organisations will require DPH tokens when constructing and generating patient-relevant studies on the platform.

REIMBURSE:

Payers/manufacturers will be required to use DPH tokens to initiate or execute smart contracts within the Reimburse module and to enroll individual patients on these smart contracts, i.e. DPH tokens will be used to facilitate the process of annexing patients to innovative pricing and reimbursement agreements.

INSIGHTS:

DPH will be used as the utility token to power each interaction with the Insights database by healthcare stakeholders i.e. DPH tokens will be used for access rights or specific data requests from the Insights platform.

EVOLVE:

DPH tokens will be used for access rights to the Evolve platform. DPH tokens will also be required to access comprehensive data and reviews related to advertised health technologies and projects.

MYHEALTH:

DPH tokens will be used for specific data requests by research organisations on the MYHEALTH platform.

When will tokens be distributed & transferrable?

Tokens will be distributed within 4 weeks after the end of the ICO, & transferrable immediately once distributed.

Contact

Get In Touch

Any questions? Reach out to us and we’ll get back to you shortly.

As seen in
partner
partner
partner
partner
partner
partner
partner
partner
partner
partner
partner
partner
partner